Chemotherapy of alveolar echinococcosis with benzimidazoles. A prospective long-term study;Chemotherapie der alveolaren echinokokkose mit benzimidazolen

Medizinische Klinik

Volumn 93, Issue 8, 1998, Pages 463-467

  Reuter, Stefan ^a,b,c   Kratzer, Wolfgang ^a,b,c   Kurz, Sabine ^a,b,c   Wellinghausen, Nele ^a,b,c   Kern, Peter ^a,b,c  

^a Abteilung Innere Medizin III

^b UNIVERSITY OF ULM   (Germany)

^c Abteilung Innere Medizin III

Author keywords

Alveolar echinococcosis; Benzimidazoles; Chemotherapy; Long term treatment

Indexed keywords

ALBENDAZOLE; BENZIMIDAZOLE DERIVATIVE; MEBENDAZOLE; ANTINEMATODAL AGENT;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ECHINOCOCCOSIS; FEMALE; FOLLOW UP; HUMAN; LUNG DISEASE; MALE; ORAL DRUG ADMINISTRATION; RECURRENCE RISK; RECURRENT DISEASE; COMPARATIVE STUDY; LIVER HYDATID CYST; LONG TERM CARE; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ALBENDAZOLE; ANTINEMATODAL AGENTS; ECHINOCOCCOSIS, HEPATIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MALE; MEBENDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 0032528770     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03042595     Document Type: Article

References (25)

1. Ammann R, Tschudi K, Ziegler M von, et al. The long-term course of 60 patients with alveolar echinococcosis in continuous therapy with niebendazole (1976-85). Klin Wochenschr 19S8;66:1060-73.
2. Ammann RW, EckertJ. Cestodes. Echinococcus. Gastroenterol Clin North Am 1996;25:655-89.
3. Ammann RW, Ilitsch N, Marincek B et al. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis, Swiss Echinococcosis Study Group. Hepatology 1994;19:735-42.
4. Bekhti A. Serum concentrations of mebendazole in patients with hydatid disease. Int J Clin Pharmacol Ther Toxicol!985;23:633-41.
5. Davis A, Pawlowski ZS, Dixon H. Multicentre clinical trials ofbenzimidazolecarbamates in human echinococcosis. 13ull World Health Organ 1986;64:383-8.
6. EckertJ. The dangerous fox tapeworm (Echinococcus mulrilocularis) and alveolar echinococcosis of humans in central Europe. Berl Münch Tierärztl Wochemchr. 1996;109:202-10.
7. Glisovic L, Kilibarda V, Redzic B, et al. Determination of albendazole and its main metabolite albendazole sulfoxide in the hydatid fluid of human echinococcal cysts using HPLC. Vojnosanit Pregl 1993;50:365-9.
8. Guan TY, Gong XY, Sun WZ, et al. Pharnucokinetics of albendazole and its metabolites in human body. Chung Kuo Yao Li. Hsueh Pao 1990;11:69-72.
9. Ilias I, Filippou N. E. multilocularis infection under treatment with albendazole for very long durations (letter). Presse Med 1997;26:667.
10. Ishizu H, UchinoJ, Sato N, et al. Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Hepatology 1997;25:528-31.
11. Jung H, Hurtado M, Sanchez M, et al. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin Neuropharmacol 1990;13:559-64.
12. Kem P. Human echinococcosis: follow-up of 23 patients treated with mebendazole. Infection 1983;11:17-24.
13. Kem P, Gerards HH. Albendazol - ein neues Anthelminthikum. ChemotlierJ 1993;2:84-92.
14. Liu YH. Continuous or intermittent treatment with albendazole? Proceedings: Arch Int Hidatidosis. XVIII Int CongrofHyd-itidology, Lisbon 1997;32:171-3.
15. Liu YH, Wang XG, Chen YT, et al. Computer tomography of liver in alveolar echinococcosis treated \\ith albendazole. Trans R Soc Trop Med Hyg 1993;87:319-21.
16. Luder PJ, Wirassek F, Weigand K, et al. Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: assessment ofbound and free druglevels in cyst fluid and of parasite vitality in operative specimens. EurJ Clin Pharmacol 1985:23:279-85.
17. Marriner SE, Morris DL, Dickson B, et al. Phannacokinetics of albendazole in man. Eur J Clin Pharmacol 1986;30:705-8.
18. Morris DL, Dykes PW, Marriner S, et al. Albendazole -objective evidence of response in human hydatid disease. JAMA 1985;253:2053-7.
19. Moskopp D, Lotterer E. Concentrations ofalbendazole in serum, cerebrospinal fluid and hydatidous brain cyst. NeurosurgRev 1993;16:35-7.
20. Prieto JG, Justel A, del Estai JL, et al. Comparative study on gastric absorption ofalbendazole and mebendazole in rats. Comp Biochem Physiol C 1991;tOO:397-400.
21. Sato N, Uchino J, Aoki S, et al. Efficacy of benzimidazoIe-rype drugs on alveolar echinococcosis (AE). Nippon ShokakibyoGakkaiZasshil994;91:l 197-204.
22. WHO; Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull World Health Organ 1996;74:231-42.
23. WilsonJF, Rausch RL. Mebend-izole and alveolar hydatid disease. Ann Trop Med Parasitol 1982;76:165-73.
24. Wilson JF, Rausch RL, McMahon BJ, et al. Parasiticide! effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992;15:234-49.
25. Wilson JF, Rausch RL, Wilson FR. Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos. Ann Surg 1995;221:3t5-23.